Literature DB >> 29558284

Implementation of a nationwide health economic consultation service to assist substance use researchers: Lessons learned.

Sean M Murphy1, Jared A Leff1, Benjamin P Linas2,3,4, Jake R Morgan3, Kathryn McCollister5, Bruce R Schackman1.   

Abstract

BACKGROUND: Health economic evaluation findings assist stakeholders in improving the quality, availability, scalability, and sustainability of evidence-based services, and in maximizing the efficiency of service delivery. The Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV (CHERISH) is a NIDA-funded multi-institutional center of excellence whose mission is to develop and disseminate health-economic research on healthcare utilization, health outcomes, and health-related behaviors that informs substance use disorder treatment policy, and HCV and HIV care of people who use substances.
METHODS: We designed a consultation service that is free to researchers whose work aligns with CHERISH's mission. The service includes up to six hours of consulting time. After prospective consultees submit their request online, they receive a screening call from the consultation service director, who connects them with a consultant with relevant expertise. Consultees and consultants complete web-based evaluations following the consultation; consultees also complete a six-month follow-up. We report on the status of the service from its inception in July 2015 through June 2017.
RESULTS: We have received 28 consultation requests (54% Early Stage Investigators, 57% MD or equivalent, 28% PhD, 61% women) on projects typically related to planning a study or grant application (93%); 71% were HIV/AIDS-related. Leading topics included cost-effectiveness (43%), statistical-analysis/econometrics (36%), cost (32%), cost-benefit (21%), and quality-of-life (18%). All consultees were satisfied with their overall experience, and felt that consultation expectations and objectives were clearly defined and the consultant's expertise was matched appropriately with their needs. Results were similar for consultants, who spent a median of 3 hours on consultations.
CONCLUSIONS: There is a need for health-economic methodological guidance among substance use, HCV, and HIV researchers. Lessons learned pertain to the feasibility of service provision, the need to implement systems to measure and improve service value, and strategies for service promotion.

Entities:  

Keywords:  HCV; HIV; economic evaluation; health economics; health services research; opioid use disorder; substance use disorders

Mesh:

Year:  2018        PMID: 29558284      PMCID: PMC6148390          DOI: 10.1080/08897077.2018.1449173

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  3 in total

1.  The Role of Science in Addressing the Opioid Crisis.

Authors:  Nora D Volkow; Francis S Collins
Journal:  N Engl J Med       Date:  2017-05-31       Impact factor: 91.245

Review 2.  A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

3.  Lifetime risk of a diagnosis of HIV infection in the United States.

Authors:  Kristen L Hess; Xiaohong Hu; Amy Lansky; Jonathan Mermin; Hildegard Irene Hall
Journal:  Ann Epidemiol       Date:  2017-02-21       Impact factor: 3.797

  3 in total
  2 in total

1.  Collaborating with health economists to advance implementation science: a qualitative study.

Authors:  Miya L Barnett; Alex R Dopp; Corinna Klein; Susan L Ettner; Byron J Powell; Lisa Saldana
Journal:  Implement Sci Commun       Date:  2020-09-29

2.  Moving beyond Aim Three: a need for a transdisciplinary approach to build capacity for economic evaluations in implementation science.

Authors:  Miya L Barnett; Nicole A Stadnick; Enola K Proctor; Alex R Dopp; Lisa Saldana
Journal:  Implement Sci Commun       Date:  2021-12-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.